Cime Therapeutics

Cime Therapeutics is a Colorado-based drug discovery company built around a "chemistry-first" platform that combines laboratory automation, materials science, synthetic organic chemistry and machine learning to synthesize and screen candidate molecules. The company emerged from stealth in April 2025 with $2.1 million in pre-seed financing, which founder and CEO James Brewster said would fund a laboratory in Colorado where the team synthesizes compounds directed at known high-profile oncology targets, beginning with transcription factors, phosphatases and kinases — target classes with comparatively few existing compounds.

The company's stated aim is to expand accessible chemical space and to sharply increase throughput relative to conventional medicinal chemistry: Brewster contrasts a typical chemist's output of 50–100 drug-like molecules per year with Cime's ambition of making hundreds of thousands per day, and the company's site cites thousands of pure, multi-step compounds synthesized per week at roughly 42 times the speed of traditional methods. Compound classes described include small molecules, molecular glues, covalent compounds and macrocycles. Brewster states a preference for synthesis over simulation on the basis that physically made molecules are closer to drug candidates. Cime is at a discovery-platform stage; no named drug candidates or clinical programs are described in the reviewed materials.

Founding story

Founder and CEO James Brewster holds a PhD in organic chemistry from the University of Texas at Austin and completed postdoctoral research at Harvard University. He joined Pfizer as a scientist on the company's oncology team in Boulder, Colorado, and after about three and a half years was laid off in 2024 when Pfizer closed the site. In August 2024 he decided to start a company to address the synthesis inefficiencies he had encountered in academia and industry, assembling a scientific advisory board that includes University of Texas at Austin chemistry professor Jonathan Sessler, former Pfizer medicinal chemist Ronald Hinklin, and chemist Pat Confalone.

Business model

Cime operates a discovery platform and invites pharmaceutical partners to access compounds and molecules generated by its automated synthesis capability, positioning itself as a partner for next-generation therapeutics rather than a clinical-stage developer.

Traction

Company materials report thousands of pure, multi-step compounds synthesized per week and roughly 42x speed versus traditional methods; the CEO describes an ambition of making hundreds of thousands of molecules per day against a typical chemist's 50–100 per year.

Latest developments

In April 2025 Cime emerged from stealth with $2.1 million in pre-seed financing, with proceeds directed at building a Colorado laboratory to synthesize compounds against oncology targets.